Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Zevra Therapeutics Presents New Data On Long-Term Safety And Efficacy Of Arimoclomol As Treatment For Niemann-Pick Disease Type C At SIMD 45th Annual Meeting

Author: Benzinga Newsdesk | April 15, 2024 05:07pm

"These observed long-term clinical benefits add to the body of evidence for arimoclomol that supports its tolerability and effectiveness in the treatment of NPC, bringing us one step closer to helping patients suffering from this relentless and fatal disease," remarked Neil F. McFarlane, President and Chief Executive Officer of Zevra. "We remain committed to continue collaborating closely with the FDA as it reviews arimoclomol's NDA ahead of our PDUFA date on September 21, 2024."

Posted In: ZVRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist